Kynurenine and its metabolites in Alzheimer's disease patients.

PURPOSE The kynurenine pathway (KP) is a major route of tryptophan metabolism. Several metabolites of this pathway are proposed to be involved in the pathogenesis of Alzheimer's disease. The aim of this study was to evaluate peripheral KP in patients with Alzheimer type dementia and a detailed analysis of correlation between kynurenine (KYN), kynurenic acid (KYNA), 3-hydroxykynurenine (3-HK), anthranilic acid (AA), quinolinic acid (QUIN) and degree of neuropsychological changes in AD. MATERIAL/METHODS The plasma concentration of tryptophan and its products degradation by kynurenine pathway were analyzed in 34 patients suffering from Alzheimer type dementia and 18 controls in similar age using high-performance liquid chromatography technique. RESULTS In demented patients we found lower tryptophan and KYNA concentrations. There was a non-significant increase of KYN, 3-HK and AA levels, and a Marked increase of QUIN in Alzheimer's disease group. We observed positive correlations between cognitive function tests and plasma KYNA levels, and inversely correlations between these tests and QUIN levels in Alzheimer type dementia. CONCLUSIONS Increased TRP degradation and simultaneous altered kynurenines levels were found in plasma of AD patients. It proves activation of peripheral kynurenine pathway in this type of dementia. The alterations of two main KYN metabolites: KYNA and QUIN seem to be associated with the impairment of the cognitive function in AD patients. This appears to offer Novel therapeutic opportunities, with the development of new compounds as a promising perspective for brain neuroprotection.

[1]  B. Brew,et al.  Quinolinic Acid Production by Macrophages Stimulated with IFN-γ, TNF-α, and IFN-α , 1997 .

[2]  E. Werner,et al.  Characteristics of interferon induced tryptophan metabolism in human cells in vitro. , 1989, Biochimica et biophysica acta.

[3]  D. Fuchs,et al.  Degradation of tryptophan in neurodegenerative disorders. , 1999, Advances in experimental medicine and biology.

[4]  B. Brew,et al.  Mechanism for Quinolinic Acid Cytotoxicity in Human Astrocytes and Neurons , 2009, Neurotoxicity Research.

[5]  W. Turski,et al.  Deficit of endogenous kynurenic acid in the frontal cortex of rats with a genetic form of absence epilepsy. , 2003, Polish journal of pharmacology.

[6]  P. Beyne,et al.  Determination of tryptophan and its kynurenine pathway metabolites in human serum by high-performance liquid chromatography with simultaneous ultraviolet and fluorimetric detection. , 1996, Journal of chromatography. B, Biomedical applications.

[7]  Satoshi Takahashi,et al.  Concentrations of serotonin and its related substances in the cerebrospinal fluid in patients with Alzheimer type dementia , 1992, Neuroscience Letters.

[8]  B. Brew,et al.  A&bgr;1-42 induces production of quinolinic acid by human macrophages and microglia , 2003, Neuroreport.

[9]  M. Heyes,et al.  Quantification of 3-hydroxykynurenine in brain by high-performance liquid chromatography and electrochemical detection. , 1988, Journal of chromatography.

[10]  János Kálmán,et al.  Decreased serum and red blood cell kynurenic acid levels in Alzheimer's disease , 2007, Neurochemistry International.

[11]  B. Brew,et al.  Effect of quinolinic acid on human astrocytes morphology and functions: implications in Alzheimer's disease , 2009, Journal of Neuroinflammation.

[12]  R. Schwarcz,et al.  The Brain Metabolite Kynurenic Acid Inhibits α7 Nicotinic Receptor Activity and Increases Non-α7 Nicotinic Receptor Expression: Physiopathological Implications , 2001, The Journal of Neuroscience.

[13]  G. Reynolds,et al.  Increased brain concentrations of a neurotoxin, 3-hydroxykynurenine, in Huntington's disease , 1992, Neuroscience Letters.

[14]  M. Lawton,et al.  Assessment of Older People: Self-Maintaining and Instrumental Activities of Daily Living , 1969 .

[15]  T. Stone,et al.  Neuropharmacology of quinolinic and kynurenic acids. , 1993, Pharmacological reviews.

[16]  S. Katz,et al.  STUDIES OF ILLNESS IN THE AGED. THE INDEX OF ADL: A STANDARDIZED MEASURE OF BIOLOGICAL AND PSYCHOSOCIAL FUNCTION. , 1963, JAMA.

[17]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[18]  D. Souza,et al.  Quinolinic acid stimulates synaptosomal glutamate release and inhibits glutamate uptake into astrocytes , 2002, Neurochemistry International.

[19]  D. Souza,et al.  In vivo Quinolinic Acid Increases Synaptosomal Glutamate Release in Rats: Reversal by Guanosine , 2005, Neurochemical Research.

[20]  Gilles J. Guillemin,et al.  The Excitotoxin Quinolinic Acid Induces Tau Phosphorylation in Human Neurons , 2009, PloS one.

[21]  C. J. Clark,et al.  Tryptophan Metabolites and Brain Disorders , 2003, Clinical chemistry and laboratory medicine.

[22]  K. Jellinger,et al.  Kynurenine metabolism in Alzheimer's disease , 1999, Journal of Neural Transmission.

[23]  B. Brew,et al.  Quinolinic acid upregulates chemokine production and chemokine receptor expression in astrocytes , 2003, Glia.

[24]  F. Moroni,et al.  Neuroprotective effects of kynurenine-3-hydroxylase inhibitors in models of brain ischemia. , 1999, Advances in experimental medicine and biology.

[25]  B. Brew,et al.  Indoleamine 2,3 dioxygenase and quinolinic acid Immunoreactivity in Alzheimer's disease hippocampus , 2005, Neuropathology and applied neurobiology.

[26]  V. Leirer,et al.  Development and validation of a geriatric depression screening scale: a preliminary report. , 1982, Journal of psychiatric research.

[27]  M. Demitrack,et al.  Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease. , 1992, Brain : a journal of neurology.

[28]  J Marshall,et al.  Cerebral blood flow in dementia. , 1975, Archives of neurology.

[29]  T. Guilarte,et al.  The role of hydrogen peroxide in the in vitro cytotoxicity of 3-hydroxykynurenine , 1990, Neurochemical Research.

[30]  H. Scharfman,et al.  Electrophysiological effects of exogenous and endogenous kynurenic acid in the rat brain: studies in vivo and in vitro , 2000, Amino Acids.

[31]  M. Beal,et al.  Kynurenine pathway abnormalities in Parkinson's disease , 1992, Neurology.

[32]  E. Holmes.  Determination of serum kynurenine and hepatic tryptophan dioxygenase activity by high-performance liquid chromatography. , 1988, Analytical biochemistry.

[33]  N. Nishiyama,et al.  3‐Hydroxykynurenine, an Endogenous Oxidative Stress Generator, Causes Neuronal Cell Death with Apoptotic Features and Region Selectivity , 1998, Journal of neurochemistry.

[34]  L. Lue,et al.  Gene expression changes by amyloid β peptide‐stimulated human postmortem brain microglia identify activation of multiple inflammatory processes , 2006, Journal of leukocyte biology.

[35]  J. Grafman,et al.  Clock Drawing in Alzheimer's Disease , 1989, Journal of the American Geriatrics Society.

[36]  T. Stone.  Kynurenines in the CNS: from endogenous obscurity to therapeutic importance , 2001, Progress in Neurobiology.

[37]  D. Fuchs,et al.  Tryptophan degradation and immune activation in Alzheimer's disease , 2000, Journal of Neural Transmission.

[38]  B. Brew,et al.  Mass spectrometric detection of quinolinic acid in microdissected Alzheimer's disease plaques , 2007 .

[39]  T. Hartmann,et al.  TNFα plus IFNγ induce the production of Alzheimer β‐amyloid peptides and decrease the secretion of APPs , 1999 .

[40]  A. Parpura-Gill,et al.  The inhibitory effects of β-amyloid on glutamate and glucose uptakes by cultured astrocytes , 1997, Brain Research.

[41]  G. Lombardi,et al.  Senile Dementia and Alzheimer's disease: Lack of changes of the cortical content of Quinolinic Acid , 1986, Neurobiology of Aging.